Mobile

A comparison of the inflammatory control of asthma provided by one inhalation of Symbicort® Turbuhaler® 160/4.5 µg/inhalation b.i.d. plus as-needed versus one inhalation of Symbicort® Turbuhaler® 320/...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004042-41

A comparison of the inflammatory control of asthma provided by one inhalation of Symbicort® Turbuhaler® 160/4.5 µg/inhalation b.i.d. plus as-needed versus one inhalation of Symbicort® Turbuhaler® 320/9 µg/inhalation b.i.d. + one inhalation of Pulmicort® Turbuhaler® 400 µg/dose b.i.d. plus Terbutaline Turbuhaler® 0.4 mg/inhalation as-needed. A 12-month, randomised, double-blind, parallel-group, active controlled, multinational, phase III B study in adult patients with asthma

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The main objective of the trial is to compare the anti-inflammatory effects of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5 µg/inhalation b.i.d. plus as-needed) versus a fixed dose treatment that includes both Symbicort Turbuhaler (320/9 µg/inhalation b.i.d.) and Pulmicort® Turbuhaler (400 µg/dose b.i.d.) plus Terbutaline Turbuhaler (0.4 mg/inhalation as-needed) on the immunopathology and remodelling of the asthmatic lung.

Critère d'inclusion

  • This is a Phase IIIB trial to be conducted in adlut asthmatic patients

Liens